Outcomes and prognostic factors of radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) for newly diagnosed, localized extranodal NK/T-cell lymphoma, nasal type (ENKL): a cooperative study in Japan.

Motoko Yamaguchi,Ritsuro Suzuki,Masahiko Oguchi,Naoko Asano,Jun Amaki,Takeshi Maeda,Nobuko Kubota,Yukio Kobayashi,Kyoko Ueda,Kana Miyazaki,Naoto Tomita,Nodoka Sekiguchi,Jun Takizawa,Bungo Saito,Tohru Murayama,Toshihiko Ando,Hideho Wada,Rie Hyo,Masatoshi Hasegawa,Naoyuki Katayama

Outcomes and prognostic factors of radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) for newly diagnosed, localized extranodal NK/T-cell lymphoma, nasal type (ENKL): a cooperative study in Japan.

2016

7541Background: A previous phase I/II study of RT-DeVIC for newly diagnosed, localized ENKL demonstrated promising efficacy (5y-overall survival [OS], 70%; 5y-progression-free survival [PFS], 63%; ...

Keywords:

Extranodal NK/T-cell lymphoma, nasal type
Carboplatin
Oncology
Pathology
Radiation therapy
Medicine
Internal medicine
Dexamethasone/etoposide/ifosfamide
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations